Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr free acid

• CAT Number: I040403
• CAS Number: 2243219-86-3
• Molecular Formula: C171H283N45O47S
• Molecular Weight: 3753.42
• Purity: ≥95%
• IUPAC Name: (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[2-[[2-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2S)-3-hydroxy-2-[[(2S)-3-(1H-imidazol-4-yl)-2-(tetradecanoylamino)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid
• InChI: InChI=1S/C171H283N45O47S/c1-18-20-21-22-23-24-25-26-27-28-32-55-131(227)190-121(80-104-85-183-90-187-104)157(249)209-126(88-217)163(255)206-124(83-134(230)231)153(245)189-97(13)143(235)213-137(94(9)10)166(258)207-120(77-101-46-30-29-31-47-101)162(254)216-140(99(15)220)169(261)208-125(84-135(232)233)160(252)205-122(81-129(179)225)158(250)203-119(79-103-58-62-106(223)63-59-103)161(253)215-139(98(14)219)168(260)199-112(53-38-44-72-177)151(243)200-116(75-91(3)4)154(246)194-113(54-45-73-184-171(181)182)149(241)192-108(49-34-40-68-173)146(238)195-114(64-65-128(178)224)152(244)196-115(66-74-264-17)145(237)188-96(12)142(234)212-136(93(7)8)165(257)197-110(51-36-42-70-175)148(240)193-109(50-35-41-69-174)150(242)202-118(78-102-56-60-105(222)61-57-102)156(248)201-117(76-92(5)6)155(247)204-123(82-130(180)226)159(251)210-127(89-218)164(256)214-138(95(11)19-2)167(259)198-111(52-37-43-71-176)147(239)191-107(48-33-39-67-172)144(236)186-86-132(228)185-87-133(229)211-141(100(16)221)170(262)263/h29-31,46-47,56-63,85,90-100,107-127,136-141,217-223H,18-28,32-45,48-55,64-84,86-89,172-177H2,1-17H3,(H2,178,224)(H2,179,225)(H2,180,226)(H,183,187)(H,185,228)(H,186,236)(H,188,237)(H,189,245)(H,190,227)(H,191,239)(H,192,241)(H,193,240)(H,194,246)(H,195,238)(H,196,244)(H,197,257)(H,198,259)(H,199,260)(H,200,243)(H,201,248)(H,202,242)(H,203,250)(H,204,247)(H,205,252)(H,206,255)(H,207,258)(H,208,261)(H,209,249)(H,210,251)(H,211,229)(H,212,234)(H,213,235)(H,214,256)(H,215,253)(H,216,254)(H,230,231)(H,232,233)(H,262,263)(H4,181,182,184)/t95-,96-,97-,98+,99+,100+,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,136-,137-,138-,139-,140-,141-/m0/s1
• InChIKey: OOYVQZJIYUSTSG-KANLGLMPSA-N
• SMILES: CCCCCCCCCCCCCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O

Myristoyl-(Lys¹²,²⁷,²⁸)-VIP-Gly-Gly-Thr free acid(CAT: I040403) is a lipidated analog of vasoactive intestinal peptide (VIP) engineered to enhance membrane permeability, receptor affinity, and in vivo stability. The addition of a myristoyl group and site-specific lysine substitutions promotes targeted delivery and extended half-life, making it ideal for research into neuroprotection, anti-inflammatory signaling, and smooth muscle relaxation. This modified peptide retains the biological activity of native VIP while offering improved pharmacokinetics. It is widely used in studies of respiratory, gastrointestinal, and central nervous system disorders. Supplied at high purity, it is suitable for advanced therapeutic research and peptide-based drug development.